TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03006172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Participants will receive oral inavolisib once daily on Days 1-28 of each 28-day cycle (Arms A, B, C, D, E, F) or Days 1-21 of each 21-day cycle (Arm G).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Participants will receive oral inavolisib once daily on Days 1-28 of each 28-day cycle (Arms A, B, C, D, E, F) or Days 1-21 of each 21-day cycle (Arm G).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Participants will receive oral inavolisib once daily on Days 1-28 of each 28-day cycle (Arms A, B, C, D, E, F) or Days 1-21 of each 21-day cycle (Arm G).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Participants will receive oral inavolisib once daily on Days 1-28 of each 28-day cycle (Arms A, B, C, D, E, F) or Days 1-21 of each 21-day cycle (Arm G).
Study: NCT01031706

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 ml 0.12% NaCl inhaled three times a day x 28 days
Study: NCT03830385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin
Description: All patients enrolled in the study will accept Paclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin as their firstline chemotherapy
Study: NCT03879395

Intervention type: PROCEDURE
Intervention: Abdominal surgery with metastasectomy
Description: Emergency or elective surgery on indications related to abdominally metastasized malignant melanoma
Study: NCT03464877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-station full-body supervised exercise program
Description: The exercise program was 6-week duration, 2-3 visits per week. It was composed of 7 stations, each consisting of numerous exercises of increasing difficulty. The exercises were grouped together as follows: Hip strengthening and control (Station 1); The squat and its variants (Station 2); Elastic bands and the Bodyblade (Station 3); Abdominal planks and their variants (Station 4); Abdominal strengthening (Station 5); Back extensor strengthening (Station 6); and Lifting techniques (Station 7).
Study: NCT03207204

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 35% Hydrogen peroxide bleaching
Description: Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 30% Carbamide peroxide bleaching
Description: Protocol: Application of 35% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Violet LED bleaching 1
Description: Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Violet LED bleaching 2
Description: Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 2 times a week.
Study: NCT03006172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Participants will receive oral inavolisib once daily on Days 1-28 of each 28-day cycle (Arms A, B, C, D, E, F) or Days 1-21 of each 21-day cycle (Arm G).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1 and 15 of Cycle 1. For subsequent cycles, participants will receive fulvestrant intramuscularly on Day 1 of each cycle.
Study: NCT03207204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photochemical protocol 1
Description: Protocol: Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photochemical protocol 2
Description: Protocol: Application of 30% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid technique 1
Description: Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 35% Hydrogen peroxide to act concomitantly with the light.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid technique 2
Description: Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 30% Carbamide peroxide to act concomitantly with the light.
Study: NCT00744276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danazol
Description: danazol applied topically once per day for 4 treatment cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danazol
Description: danazol applied topically once per day for 4 treatment cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danazol
Description: danazol applied topically once per day for 4 treatment cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo topically applied once daily for 4 treatment cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo topically applied once daily for 4 treatment cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo topically applied once daily for 4 treatment cycles
Study: NCT03514589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV tetracosactide
Description: Bioavailability of nasal synacthen compared to IV comparator
Study: NCT04004702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam 500mg twice a day
Study: NCT02973828

Intervention type: PROCEDURE
Intervention: Imaging
Description: This is an observational study only, with no interventions. Volunteers will undergo MRI imaging on the MR Linac, however this will not affect, change or initiate any intervention, or change to their care path.

Intervention type: PROCEDURE
Intervention: Imaging
Description: This is an observational study only, with no interventions. Volunteers will undergo MRI imaging on the MR Linac, however this will not affect, change or initiate any intervention, or change to their care path.

Intervention type: PROCEDURE
Intervention: Imaging
Description: This is an observational study only, with no interventions. Volunteers will undergo MRI imaging on the MR Linac, however this will not affect, change or initiate any intervention, or change to their care path.

Intervention type: PROCEDURE
Intervention: Imaging
Description: This is an observational study only, with no interventions. Volunteers will undergo MRI imaging on the MR Linac, however this will not affect, change or initiate any intervention, or change to their care path.
Study: NCT04633356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-portal pressure gradient measurement (PPGM)
Description: EUS-guided PPGM is performed under conscious sedation. An OGD would be performed to evaluate for findings consistent with portal hypertension such as varices and portal hypertensive gastropathy. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein. A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle. Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The process is repeated for the hepatic vein. The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
Study: NCT03009500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study: NCT02376010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study: NCT04205812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: INCMGA00012 administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: INCMGA00012 administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
Study: NCT03712293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BBB Disruption with Chemotherapy Arm
Description: The ExAblate BBB disruption of targets associated with enhancing post-resection MRI imaging procedure will be performed with ExAblate 4000 type 2.0 system and will coincide with on one of three first days of each planned TMZ adjuvant therapy cycle as one procedure per cycle.
Study: NCT01619943

Intervention type: OTHER
Intervention: no intervention
Description: clinical follow up

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02142439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Three times per week with strength training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Three times per week with strength training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Three times per week with strength training
Study: NCT03006172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1 and 15 of Cycle 1. For subsequent cycles, participants will receive fulvestrant intramuscularly on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1 and 15 of Cycle 1. For subsequent cycles, participants will receive fulvestrant intramuscularly on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Participants will receive once daily oral doses of letrozole 2.5 mg on Days 1-28 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Participants will receive once daily oral doses of letrozole 2.5 mg on Days 1-28 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Participants will receive once daily oral doses of letrozole 2.5 mg on Days 1-28 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Participants will receive once daily oral doses of letrozole 2.5 mg on Days 1-28 of each cycle.
Study: NCT04205812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
Study: NCT03006172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Participants will receive once daily oral doses of palbociclib 125 mg on Days 1-21 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Participants will receive once daily oral doses of palbociclib 125 mg on Days 1-21 of each cycle.
Study: NCT04205812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle for 4 cycles.
Study: NCT04269265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever Vaccine
Description: YF-VAX®, Yellow Fever Vaccine, for subcutaneous use
Study: NCT04245098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carpal tunnel syndrome surgery
Description: Biopsy
Study: NCT03006172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Participants will receive once daily oral doses of palbociclib 125 mg on Days 1-21 of each cycle.
Study: NCT03977155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS-589
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS-589
Description: oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets
Study: NCT00467493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Study: NCT01245023

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic adhesiolysis
Description: Laparoscopic adhesiolysis and Sprayshield

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-surgery
Description: skin incisions without laparoscopy or related procedures
Study: NCT00336063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03009500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-Medrol Injectable Product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (Sodium Chloride) solution
Study: NCT03006172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Participants will receive once daily oral doses of palbociclib 125 mg on Days 1-21 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive oral metformin once daily, starting on Cycle 1, Day 1, as tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles, until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive pertuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 840 mg for Cycle 1 and a dose of 420 mg for subsequent cycles, until disease progression or unacceptable toxicity.
Study: NCT03009500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of 2% lidocaine at each injection site to reduce discomfort of the study participants from the injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of 2% lidocaine at each injection site to reduce discomfort of the study participants from the injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of 2% lidocaine at each injection site to reduce discomfort of the study participants from the injections
Study: NCT01108120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous intra-femoral thrombolysis group
Description: Firstly, 20 0000 u urokinase is injected to the diseased foot via catheter. Then, continuous injection of urokinase via femoral artery by a artery mini-pump (100 ml 0.9% sodium chloride + 100 0000 unit urokinase at a rate of 4 ml per hour) is taken for 7 - 9 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy group
Description: All patients receive an intravenous injection of prostaglandin E1 20 ug per day during hospitalization period.
Study: NCT04798456

Intervention type: BEHAVIORAL
Intervention: Coma scales
Description: CRS-R and GOSE

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging, electrophysiology, body signals, and brain stimulation
Description: MRI, fMRI, EEG, TMS-EEG, Olfaction, Respiration, EKG

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: several questionnaires and an interview with the caregiver
Study: NCT03594526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal support to become mother
Description: AMACOM-PRI: Apoyo Materno para Convertirse en Madre - Primerizas. Maternal support to become first-time mothers is an intervention based on the mid-range nursing theory of Ramona Mercer, whose purpose is to empower first-time mothers in their new maternal role, favoring the mother-child bond, strengthening social support and maternal self-efficacy, consists of.~1. Four Home visits , in the first week; first month of baby life; at three months; and the fourth postpartum month.~2. Four Educational sessions and support sessions for maternal empowerment in each home visit.~3. Telephone follow-up: at 15 days; a month and a half; at two and a half months; and three and a half months postpartum.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: usual care
Description: This intervention is usual care, which consists of:~1. care of the mother and her newborn during the puerperium~2. Teaching about breastfeeding.
Study: NCT03278158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN-D0501, 8 mg/tablet
Description: Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet
Study: NCT00336063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT01891058

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug-shock vs shock only
Description: procainamide followed by electrocardioversion if necessary vs cardioversion only.
Study: NCT01083238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: 120mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: 120mg single oral dose
Study: NCT01942447

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study: NCT04469725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 5 milligram per kilogram, every 2 weeks
Study: NCT01309724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: USCOM-guided fluid administration
Description: Patients in the intervention group underwent hemodynamic measurements with the ultrasound cardiac output monitor. Based on these measurements, patients were guided through a fluid resuscitation protocol.